vs
Medicus Pharma Ltd.（MDCX）与RAPT Therapeutics, Inc.（RAPT）财务数据对比。点击上方公司名可切换其他公司
Horizon Therapeutics plc是一家生物制药企业，专注于罕见病和风湿性疾病相关药物的研发、生产及商业化，致力于满足相关患者的迫切治疗需求。其产品主要在美国市场销售，2019年美国市场营收占全球总营收的97%，2023年10月被安进公司收购。
MDCX vs RAPT — 直观对比
营收规模更大
MDCX
是对方的Infinity倍
$0
损益表 — Q3 FY2025 vs Q3 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $11.6K | $0 |
| 净利润 | $-20.9M | $-31.4M |
| 毛利率 | — | — |
| 营业利润率 | -0.1% | — |
| 净利率 | -180917.3% | — |
| 营收同比 | -79.2% | — |
| 净利润同比 | -818.7% | -47.7% |
| 每股收益（稀释后） | $-1.12 | $-0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDCXRAPT
| Q3 25 | $11.6K | — | ||
| Q2 25 | $40.0K | — | ||
| Q3 24 | $55.5K | — | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 | ||
| Q4 22 | — | $0 | ||
| Q3 22 | — | $0 | ||
| Q2 22 | — | $886.0K |
净利润MDCXRAPT
| Q3 25 | $-20.9M | — | ||
| Q2 25 | $-6.2M | — | ||
| Q3 24 | $-2.3M | — | ||
| Q3 23 | — | $-31.4M | ||
| Q2 23 | — | $-25.3M | ||
| Q4 22 | — | $-23.0M | ||
| Q3 22 | — | $-21.2M | ||
| Q2 22 | — | $-19.2M |
营业利润率MDCXRAPT
| Q3 25 | -0.1% | — | ||
| Q2 25 | -15038.7% | — | ||
| Q3 24 | -4204.8% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | -2134.2% |
净利率MDCXRAPT
| Q3 25 | -180917.3% | — | ||
| Q2 25 | -15438.7% | — | ||
| Q3 24 | -4104.8% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | -2165.2% |
每股收益（稀释后）MDCXRAPT
| Q3 25 | $-1.12 | — | ||
| Q2 25 | $-0.43 | — | ||
| Q3 24 | $-0.24 | — | ||
| Q3 23 | — | $-0.82 | ||
| Q2 23 | — | $-0.66 | ||
| Q4 22 | — | $-0.64 | ||
| Q3 22 | — | $-0.63 | ||
| Q2 22 | — | $-0.62 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.7M | $184.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-910.1K | $172.8M |
| 总资产 | $10.0M | $199.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MDCXRAPT
| Q3 25 | $8.7M | — | ||
| Q2 25 | $9.7M | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $184.8M | ||
| Q2 23 | — | $205.0M | ||
| Q4 22 | — | $249.1M | ||
| Q3 22 | — | $195.4M | ||
| Q2 22 | — | $207.3M |
股东权益MDCXRAPT
| Q3 25 | $-910.1K | — | ||
| Q2 25 | $3.2M | — | ||
| Q3 24 | $4.8M | — | ||
| Q3 23 | — | $172.8M | ||
| Q2 23 | — | $199.7M | ||
| Q4 22 | — | $245.2M | ||
| Q3 22 | — | $189.3M | ||
| Q2 22 | — | $202.1M |
总资产MDCXRAPT
| Q3 25 | $10.0M | — | ||
| Q2 25 | $11.9M | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $199.7M | ||
| Q2 23 | — | $220.8M | ||
| Q4 22 | — | $266.2M | ||
| Q3 22 | — | $209.5M | ||
| Q2 22 | — | $222.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.8M | $-21.9M |
| 自由现金流经营现金流 - 资本支出 | — | $-21.9M |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-91.1M |
8季度趋势，按日历期对齐
经营现金流MDCXRAPT
| Q3 25 | $-6.8M | — | ||
| Q2 25 | $-5.5M | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $-21.9M | ||
| Q2 23 | — | $-28.8M | ||
| Q4 22 | — | $-22.8M | ||
| Q3 22 | — | $-17.1M | ||
| Q2 22 | — | $-15.2M |
自由现金流MDCXRAPT
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $-21.9M | ||
| Q2 23 | — | $-29.0M | ||
| Q4 22 | — | $-22.9M | ||
| Q3 22 | — | $-17.2M | ||
| Q2 22 | — | $-15.8M |
自由现金流率MDCXRAPT
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | -1778.9% |
资本支出强度MDCXRAPT
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | 63.9% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
